BMRN BioMarin Pharmaceutical Inc.

69.15
+1.25  (+2%)
Previous Close 67.9
Open 68.05
Price To Book 4.19
Market Cap 12,409,849,785
Shares 179,462,759
Volume 1,663,176
Short Ratio
Av. Daily Volume 1,283,041
Stock charts supplied by TradingView

NewsSee all news

  1. BioMarin to Host Third Quarter 2019 Financial Results Conference Call and Webcast on Wednesday, October 23 at 4:30pm ET

    SAN RAFAEL, Calif., Oct. 9, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and

  2. BioMarin Promotes Lon Cardon, Ph.D. to Chief Scientific Strategy Officer

    SAN RAFAEL, Calif., Oct. 7, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced the promotion of Lon Cardon, Ph.D. to Chief Scientific Strategy Officer, a newly created role to enrich

  3. BioMarin to Participate in Jefferies Gene Therapy/Editing Summit on October 8, 2019 in New York

    SAN RAFAEL, Calif., Oct. 1, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Robert Baffi, Ph.D., President of Global Manufacturing and Technical Operations, will participate in a

  4. BioMarin, Pioneer in Phenylketonuria (PKU) Therapies, Submits Clinical Trial Application (CTA) in U.K. for Investigational Gene Therapy for PKU

    SAN RAFAEL, Calif., Sept. 26, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), a pioneer in treatments for rare disease Phenylketonuria (PKU) and in gene therapies, today announced that it has submitted a

  5. BioMarin to Participate in Morgan Stanley 17th Annual Global Healthcare Conference on September 10, 2019 in New York

    SAN RAFAEL, Calif., Sept. 9, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), today announced that Dan Spiegelman, Executive Vice President and Chief Financial Officer and Henry Fuchs, M.D., President,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 interim data released May 28, 2019 - Factor VIII level =36 (23 to 26 weeks).
Valoctocogene roxaparvovec (BMN 270)
Hemophilia A
Phase 3 top-line data due end of 2019.
Vosoritide
Achondroplasia
Approval announced May 24, 2018.
Palynziq (Pegvaliase)
Phenylketonuria (PKU)
Program terminated June 2016
Reveglucosidase alfa (BMN 701)
Pompe Disease
Approved February 14, 2014.
Vimizim (GALNS)
(MPS IVA) Morquio A Syndrome
PDUFA date extended by three months to April 27 2017. Approval announced April 27, 2017.
Cerliponase alfa
Batten Disease
CRL issued January 14, 2016.
Kyndrisa
Duchenne Muscular Dystrophy (DMD)
BLA filing due 4Q 2019.
Valoctocogene roxaparvovec (BMN 270)
Hemophilia A
Phase 1/2 dosing has commenced - noted May 15, 2018.
Valoctocogene roxaparvovec (BMN 270)
Hemophilia A with with pre-existing AAV5 antibodies
Phase 3 top-line data due end of 2019.
Vosoritide
Achondroplasia - young children

Latest News

  1. BioMarin to Host Third Quarter 2019 Financial Results Conference Call and Webcast on Wednesday, October 23 at 4:30pm ET

    SAN RAFAEL, Calif., Oct. 9, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and

  2. BioMarin Promotes Lon Cardon, Ph.D. to Chief Scientific Strategy Officer

    SAN RAFAEL, Calif., Oct. 7, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced the promotion of Lon Cardon, Ph.D. to Chief Scientific Strategy Officer, a newly created role to enrich

  3. BioMarin to Participate in Jefferies Gene Therapy/Editing Summit on October 8, 2019 in New York

    SAN RAFAEL, Calif., Oct. 1, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Robert Baffi, Ph.D., President of Global Manufacturing and Technical Operations, will participate in a

  4. BioMarin, Pioneer in Phenylketonuria (PKU) Therapies, Submits Clinical Trial Application (CTA) in U.K. for Investigational Gene Therapy for PKU

    SAN RAFAEL, Calif., Sept. 26, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), a pioneer in treatments for rare disease Phenylketonuria (PKU) and in gene therapies, today announced that it has submitted a

  5. BioMarin to Participate in Morgan Stanley 17th Annual Global Healthcare Conference on September 10, 2019 in New York

    SAN RAFAEL, Calif., Sept. 9, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), today announced that Dan Spiegelman, Executive Vice President and Chief Financial Officer and Henry Fuchs, M.D., President,

  6. BioMarin to Participate in Morgan Stanley 17th Annual Global Healthcare Conference on September 10, 2019 in New York

    SAN RAFAEL, Calif., Aug. 28, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Dan Spiegelman, Executive Vice President and Chief Financial Officer, will present at the Morgan Stanley